John J. Ko

1.4k total citations
23 papers, 443 citations indexed

About

John J. Ko is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Pathology and Forensic Medicine. According to data from OpenAlex, John J. Ko has authored 23 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Pediatrics, Perinatology and Child Health and 5 papers in Pathology and Forensic Medicine. Recurrent topics in John J. Ko's work include Porphyrin Metabolism and Disorders (10 papers), Heme Oxygenase-1 and Carbon Monoxide (9 papers) and Neonatal Health and Biochemistry (5 papers). John J. Ko is often cited by papers focused on Porphyrin Metabolism and Disorders (10 papers), Heme Oxygenase-1 and Carbon Monoxide (9 papers) and Neonatal Health and Biochemistry (5 papers). John J. Ko collaborates with scholars based in United States, United Kingdom and South Korea. John J. Ko's co-authors include Kristen Johnson, Rahul Sasané, Vivian Herrera, Huanxue Zhou, Feng Lin, Paul Wicks, Steve Arcona, Yujin Park, Aneesh Thomas George and Syed Atif Raza and has published in prestigious journals such as Blood, PLoS ONE and Neurology.

In The Last Decade

John J. Ko

20 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John J. Ko United States 11 134 102 100 70 54 23 443
Kristen McCullough United States 16 181 1.4× 28 0.3× 76 0.8× 160 2.3× 103 1.9× 53 805
Anthony Louder United States 11 69 0.5× 72 0.7× 20 0.2× 33 0.5× 26 0.5× 17 353
Huah Shin Ng Australia 14 71 0.5× 49 0.5× 167 1.7× 30 0.4× 60 1.1× 36 548
Joshua Posner United States 11 21 0.2× 104 1.0× 62 0.6× 35 0.5× 19 0.4× 24 326
Gurvaneet Randhawa United States 14 230 1.7× 91 0.9× 36 0.4× 116 1.7× 72 1.3× 28 597
Mwangi J. Murage United States 12 32 0.2× 65 0.6× 35 0.3× 61 0.9× 29 0.5× 31 427
Ansgar Hebborn Switzerland 8 46 0.3× 129 1.3× 29 0.3× 47 0.7× 18 0.3× 12 481
F.S. Mennini Italy 9 40 0.3× 44 0.4× 41 0.4× 27 0.4× 27 0.5× 45 343
Aaron Galaznik United States 13 74 0.6× 32 0.3× 121 1.2× 10 0.1× 94 1.7× 43 460
Eline van Overbeeke Belgium 14 38 0.3× 322 3.2× 17 0.2× 75 1.1× 85 1.6× 26 674

Countries citing papers authored by John J. Ko

Since Specialization
Citations

This map shows the geographic impact of John J. Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Ko more than expected).

Fields of papers citing papers by John J. Ko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Ko. The network helps show where John J. Ko may publish in the future.

Co-authorship network of co-authors of John J. Ko

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Ko. A scholar is included among the top collaborators of John J. Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Ko. John J. Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kim, Jae-Hwan, John J. Ko, Hun‐Young Yoon, Jin‐Hyeok Hwang, & Kidong Eom. (2021). Clinical and imaging findings of walled-off pancreatic necrosis misdiagnosed as an intra-abdominal neoplasia in a Schnauzer dog: A case report. Veterinární Medicína. 66(1). 32–39.
4.
Gill, Liz, et al.. (2021). Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study. Orphanet Journal of Rare Diseases. 16(1). 187–187. 10 indexed citations
5.
Ventura, P., Herbert L. Bonkovsky, Laurent Gouya, et al.. (2021). Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study. Liver International. 42(1). 161–172. 61 indexed citations
6.
Bonkovsky, Herbert L., Paolo Ventura, Paula Aguilera, et al.. (2021). S1170 Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyria: 24-Month Interim Analysis of the Phase 3 ENVISION Randomized Clinical Trial. The American Journal of Gastroenterology. 116(1). S545–S546. 2 indexed citations
7.
Cohen, Aaron, Thomas G. DeLoughery, Michelle Nguyen, et al.. (2020). Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria. PLoS ONE. 15(7). e0235574–e0235574. 33 indexed citations
8.
Karki, Chitra, et al.. (2020). A166 ANALYSIS OF SYMPTOMS, DIAGNOSTIC PATTERNS, AND CANADIAN PROVIDER PERSPECTIVE OF ACUTE HEPATIC PORPHYRIA. Journal of the Canadian Association of Gastroenterology. 3(Supplement_1). 31–32.
9.
Ko, John J., et al.. (2018). The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. Journal of Medical Internet Research. 20(10). e11168–e11168. 38 indexed citations
10.
Rudnick, Sean, Hélio Pedro, John J. Ko, et al.. (2018). The Patient Odyssey to Confirmed Acute Hepatic Porphyria Diagnosis: Clinical Characteristics and Healthcare Utilization of Patients Preceding Diagnosis of Acute Hepatic Porphyria. The American Journal of Gastroenterology. 113(Supplement). S500–S501. 1 indexed citations
11.
Johnson, Kristen, Huanxue Zhou, Feng Lin, John J. Ko, & Vivian Herrera. (2017). Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Journal of Managed Care & Specialty Pharmacy. 23(8). 844–852. 66 indexed citations
12.
Park, Yujin, et al.. (2017). The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review. Journal of Managed Care & Specialty Pharmacy. 23(8). 893–901. 46 indexed citations
13.
Ko, John J., et al.. (2016). Real World Comparison of Patient Adherence and Persistence to Fingolimod vs. Dimethyl Fumarate (P3.101). Neurology. 86(16_supplement). 1 indexed citations
14.
Ko, John J., Jackie Lu, Karen L. Rascati, et al.. (2016). Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes. Journal of Managed Care & Specialty Pharmacy. 22(1). 32–37. 21 indexed citations
15.
Zhou, Huanxue, Kristen Johnson, John J. Ko, et al.. (2016). Real World Relapse Rates of Glatiramer Acetate Patients Switching to Fingolimod or Interferon Beta-1a Versus Remaining on Glatiramer Acetate (P6.181). Neurology. 86(16_supplement). 1 indexed citations
16.
17.
Arcona, Steve, et al.. (2016). Increasing Patient Involvement in Drug Development. Value in Health. 19(6). 869–878. 75 indexed citations
18.
Sasané, Rahul, Lawrence Rasouliyan, Božena Katić, et al.. (2016). Treatment Satisfaction and Side Effect Experience with Fingolimod and Dimethyl Fumarate for Multiple Sclerosis: Findings from an Online Patient Cohort (P3.119). Neurology. 86(16_supplement). 1 indexed citations
19.
20.
Ko, John J., et al.. (2000). Electron beam tomography comparison of culprit and non-culprit coronary arteries in patients with acute myocardial infarction. The American Journal of Cardiology. 85(11). 1357–1359. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristen McCullough Breakdown of academic impact, for papers by Anthony Louder Breakdown of academic impact, for papers by Huah Shin Ng Breakdown of academic impact, for papers by Joshua Posner Breakdown of academic impact, for papers by Gurvaneet Randhawa Breakdown of academic impact, for papers by Mwangi J. Murage Breakdown of academic impact, for papers by Ansgar Hebborn Breakdown of academic impact, for papers by F.S. Mennini Breakdown of academic impact, for papers by Aaron Galaznik Breakdown of academic impact, for papers by Eline van Overbeeke
Rankless by CCL
2026